{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:53:30Z","timestamp":1791665610424,"version":"4.3.4"},"reference-count":73,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses several cardiometabolic risk factors (obesity, insulin resistance, diabetes, and dyslipidemia), in addition to hepatic steatosis. Therefore, treatment is often challenging and frequently involves polypharmacy. This study investigated whether the combination of empagliflozin\/metformin improves MASLD disease outcomes in an experimental model of metabolic syndrome (MS). To evaluate the efficacy of the empagliflozin\/metformin (12.5\/850 mg\/kg\/day\/30 days) combination, male Wistar rats (200\u2013220 g) were fed a Western-type diet and sugary drink to induce MS. Biochemical parameters, markers of liver damage, oxidative stress, and histopathological analysis were assessed. Also, the expression of transcription factors associated with carbohydrate and lipid metabolism and the modulation of oxidative stress were assessed. The analyses were performed with the combination and with the drugs independently. The combination empagliflozin\/metformin decreased body weight, plasma triglycerides, and total cholesterol levels, while improving fasting blood glucose, oral glucose tolerance test, and plasma HDL-cholesterol levels. Additionally, it prevented hepatic hypertrophy, liver damage at both biochemical and histological levels, and intrahepatic lipid accumulation. The combination also demonstrated a significantly greater effect in improving mitochondrial function and reducing oxidative stress by modulating the Nrf2-mediated pathway. The empagliflozin\/metformin combination therapy mitigates MASLD progression, likely by improving liver and mitochondrial function, and attenuating oxidative stress. Notably, co-therapy shows greater beneficial effects than single treatments. This protective effect appears to involve modulation of key transcription factors regulating lipid and carbohydrate metabolism, as well as influencing endogenous antioxidant defenses.<\/jats:p>","DOI":"10.3390\/ijms26189010","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:59:51Z","timestamp":1758088791000},"page":"9010","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Combination Empagliflozin\/Metformin Attenuates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Diet-Induced Experimental Rat Model"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6645-9054","authenticated-orcid":false,"given":"Oscar Ren\u00e9","family":"Zambrano-V\u00e1squez","sequence":"first","affiliation":[{"name":"Doctorado en Ciencias Biol\u00f3gicas y de la Salud, Universidad Aut\u00f3noma Metropolitana, Mexico City 14387, Mexico"},{"name":"Departamento de Fisiopatolog\u00eda Cardio-Renal, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Cortes-Camacho","sequence":"additional","affiliation":[{"name":"Doctorado en Ciencias Biol\u00f3gicas y de la Salud, Universidad Aut\u00f3noma Metropolitana, Mexico City 14387, Mexico"},{"name":"Departamento de Fisiopatolog\u00eda Cardio-Renal, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0649-9338","authenticated-orcid":false,"given":"Juan Carlos","family":"Cabrera-Angeles","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Mexico City 11340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5856-1137","authenticated-orcid":false,"given":"Ana Lilia","family":"Hern\u00e1ndez-Alba","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Mexico City 11340, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Enrique","family":"Garc\u00eda-Arroyo","sequence":"additional","affiliation":[{"name":"Departamento de Fisiopatolog\u00eda Cardio-Renal, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4323-4988","authenticated-orcid":false,"given":"Jorge Ismael","family":"Casta\u00f1eda-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Department of Biological Systems, Universidad Aut\u00f3noma Metropolitana-Xochimilco, Mexico City 04960, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-5593","authenticated-orcid":false,"given":"Elena","family":"Ar\u00e9chaga-Ocampo","sequence":"additional","affiliation":[{"name":"Department of Natural Sciences, Universidad Aut\u00f3noma Metropolitana-Cuajimalpa, Mexico City 05348, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Emiliano","family":"Aparicio-Trejo","sequence":"additional","affiliation":[{"name":"Departamento de Fisiopatolog\u00eda Cardio-Renal, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Del","family":"Valle-Mondrag\u00f3n","sequence":"additional","affiliation":[{"name":"Departamento de Farmacolog\u00eda, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-7695","authenticated-orcid":false,"given":"Constanza Estefan\u00eda","family":"Mart\u00ednez-Olivares","sequence":"additional","affiliation":[{"name":"Experimental Pathology Department, Instituto Nacional de Ciencia M\u00e9dicas y Nutrici\u00f3n \u201cSalvador Zubir\u00e1n\u201d, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-3833","authenticated-orcid":false,"given":"Rogelio","family":"Hern\u00e1ndez-Pando","sequence":"additional","affiliation":[{"name":"Experimental Pathology Department, Instituto Nacional de Ciencia M\u00e9dicas y Nutrici\u00f3n \u201cSalvador Zubir\u00e1n\u201d, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Gabriela","family":"S\u00e1nchez-Lozada","sequence":"additional","affiliation":[{"name":"Departamento de Fisiopatolog\u00eda Cardio-Renal, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9238-4202","authenticated-orcid":false,"given":"Horacio","family":"Osorio-Alonso","sequence":"additional","affiliation":[{"name":"Departamento de Fisiopatolog\u00eda Cardio-Renal, Instituto Nacional de Cardiolog\u00eda Ignacio Ch\u00e1vez, Mexico City 14080, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"120956","DOI":"10.1016\/j.lfs.2022.120956","article-title":"Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms","volume":"308","author":"Shaaban","year":"2022","journal-title":"Life Sci."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Yu, L., Hong, W., Lu, S., Li, Y., Guan, Y., Weng, X., and Feng, Z. (2022). The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.780496"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: An update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jhep.2023.08.021","article-title":"Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD","volume":"80","author":"Chen","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_8","first-page":"8","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD)","volume":"4","author":"Wong","year":"2024","journal-title":"Metab. Target Organ. Damage"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_10","first-page":"129","article-title":"Risk factors for adiposity in the urban population and influence on the prevalence of overweight and obesity","volume":"20","author":"Remus","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yin, X., Guo, X., Liu, Z., and Wang, J. (2023). Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032844"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41419-018-0531-z","article-title":"Hepatic steatosis associated with decreased \u03b2-oxidation and mitochondrial function contributes to cell damage in obese mice after thermal injury","volume":"9","author":"Diao","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Radosavljevic, T., Brankovic, M., Samardzic, J., Djureti\u0107, J., Vukicevic, D., Vucevic, D., and Jakovljevic, V. (2024). Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches. Antioxidants, 13.","DOI":"10.3390\/antiox13080906"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"154770","DOI":"10.1016\/j.metabol.2021.154770","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","volume":"119","author":"Mikhailidis","year":"2021","journal-title":"Metabolism"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.livres.2023.11.003","article-title":"In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: Mechanism and pharmacological interventions","volume":"7","author":"Zhu","year":"2023","journal-title":"Liver Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jdi.12888","article-title":"Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial","volume":"10","author":"Feng","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ntikoudi, A., Papachristou, A., Tsalkitzi, A., Margari, N., Evangelou, E., and Vlachou, E. (2025). Metabolic-Associated Steatotic Liver Disease (MASLD) and Type 2 Diabetes: Mechanisms, Diagnostic Approaches, and Therapeutic Interventions. Diabetology, 6.","DOI":"10.3390\/diabetology6040023"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12325-013-0084-6","article-title":"Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"31","author":"Doycheva","year":"2014","journal-title":"Adv. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: An overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1007\/s00431-023-05169-9","article-title":"The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials","volume":"182","author":"Gkiourtzis","year":"2023","journal-title":"Eur. J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nasiri-Ansari, N., Nikolopoulou, C., Papoutsi, K., Kyrou, I., Mantzoros, C.S., Kyriakopoulos, G., Chatzigeorgiou, A., Kalotychou, V., Randeva, M.S., and Chatha, K. (2021). Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-\/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020818"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bica, I.-C., Stoica, R.A., Salmen, T., Jane\u017e, A., Vol\u010dan\u0161ek, \u0160., Popovic, D., Muzurovic, E., Rizzo, M., and Stoian, A.P. (2023). The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials. Medicina, 59.","DOI":"10.3390\/medicina59061136"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2147\/DMSO.S422327","article-title":"Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice","volume":"16","author":"Niu","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.3748\/wjg.v16.i42.5286","article-title":"Histopathology of nonalcoholic fatty liver disease","volume":"16","author":"Brunt","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arroyo, F.E., Gonzaga-S\u00e1nchez, G., Tapia, E., Mu\u00f1oz-Jim\u00e9nez, I., Manterola-Romero, L., Osorio-Alonso, H., Arellano-Buend\u00eda, A.S., Pedraza-Chaverri, J., Roncal-Jim\u00e9nez, C.A., and Lanaspa, M.A. (2021). Osthol Ameliorates Kidney Damage and Metabolic Syndrome Induced by a High-Fat\/High-Sugar Diet. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052431"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Arroyo, F.E., Gonzaga-S\u00e1nchez, G., Silva-Palacios, A., Rold\u00e1n, F.J., Loredo-Mendoza, M.L., Alvarez-Alvarez, Y.Q., Coyotl, J.A.d.L.S., Orozco, K.A.V., Tapia, E., and Osorio-Alonso, H. (2023). Osthole Prevents Heart Damage Induced by Diet-Induced Metabolic Syndrome: Role of Fructokinase (KHK). Antioxidants, 12.","DOI":"10.3390\/antiox12051023"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e16132","DOI":"10.7717\/peerj.16132","article-title":"Antioxidant and anti-inflammatory effects of allicin in the kidney of an experimental model of metabolic syndrome","volume":"11","author":"Buendia","year":"2023","journal-title":"PeerJ"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Simoes, I.C.M., Karkucinska-Wieckowska, A., Janikiewicz, J., Szymanska, S., Pronicki, M., Dobrzyn, P., Dabrowski, M., Dobrzyn, A., Oliveira, P.J., and Zischka, H. (2020). Western Diet Causes Obesity-Induced Nonalcoholic Fatty Liver Disease Development by Differentially Compromising the Autophagic Response. Antioxidants, 9.","DOI":"10.3390\/antiox9100995"},{"key":"ref_32","first-page":"280","article-title":"Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease","volume":"37","author":"Makri","year":"2024","journal-title":"Ann. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"101143","DOI":"10.1016\/j.molmet.2020.101143","article-title":"Metabolic drivers of non-alcoholic fatty liver disease","volume":"50","author":"Bence","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: A major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Caturano, A., Galiero, R., Loffredo, G., Vetrano, E., Medicamento, G., Acierno, C., Rinaldi, L., Marrone, A., Salvatore, T., and Monda, M. (2023). Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020322"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/07435800.2020.1713802","article-title":"Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice","volume":"45","author":"Tahara","year":"2020","journal-title":"Endocr. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jgf2.723","article-title":"Empagliflozin add-on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: An open-label, single-center, pilot clinical trial","volume":"25","author":"Esmaeili","year":"2024","journal-title":"J. Gen. Fam. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus","volume":"65","author":"Lai","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.endonu.2016.06.003","article-title":"Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus","volume":"63","author":"Romera","year":"2016","journal-title":"Endocrinol. Nutr. Eng. Ed."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/livers2010003","article-title":"Oxidative Stress in Non-Alcoholic Fatty Liver Disease","volume":"2","author":"Smirne","year":"2022","journal-title":"Livers"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wang, Y., Ding, Y., Sun, P., Zhang, W., Xin, Q., Wang, N., Niu, Y., Chen, Y., Luo, J., and Lu, J. (2022). Empagliflozin-Enhanced Antioxidant Defense Attenuates Lipotoxicity and Protects Hepatocytes by Promoting FoxO3a- and Nrf2-Mediated Nuclear Translocation via the CAMKK2\/AMPK Pathway. Antioxidants, 11.","DOI":"10.3390\/antiox11050799"},{"key":"ref_42","first-page":"E730","article-title":"Treatment of nonalcoholic fatty liver disease: Role of AMPK","volume":"311","author":"Smith","year":"2016","journal-title":"Am. J. Physiol. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","article-title":"Innate Immunity and Inflammation in NAFLD\/NASH","volume":"61","author":"Arrese","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Albhaisi, S., and Noureddin, M. (2021). Current and Potential Therapies Targeting Inflammation in NASH. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.767314"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Jani\u0107, M., Jane\u017e, A., \u0160abovi\u0107, M., El-Tanani, M., Rangraze, I., Rizzo, M., and Lunder, M. (2024). Glucometabolic Efficacy of the Empagliflozin\/Metformin Combination in People with Type 1 Diabetes and Increased Cardiovascular Risk: A Sub-Analysis of a Pilot Randomized Controlled Trial. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226860"},{"key":"ref_49","first-page":"1","article-title":"Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes","volume":"2022","author":"Cankar","year":"2022","journal-title":"J. Diabetes Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"108610","DOI":"10.1016\/j.jdiacomp.2023.108610","article-title":"Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"37","author":"Shi","year":"2023","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.nbd.2010.05.030","article-title":"Acute oxidative stress and systemic Nrf2 activation by the ketogenic diet","volume":"40","author":"Milder","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1111\/dom.14503","article-title":"Sodium-glucose cotransporter-2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation","volume":"23","author":"Moon","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1700903","DOI":"10.1002\/mnfr.201700903","article-title":"Sugary Kefir Strain Lactobacillus mali APS1 Ameliorated Hepatic Steatosis by Regulation of SIRT-1\/Nrf-2 and Gut Microbiota in Rats","volume":"62","author":"Chen","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.freeradbiomed.2009.11.007","article-title":"Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis","volume":"48","author":"Chowdhry","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/atm.2019.09.03","article-title":"The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus","volume":"7","author":"Leng","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Qiao, P., Jia, Y., Ma, A., He, J., Shao, C., Li, X., Wang, S., Yang, B., and Zhou, H. (2022). Dapagliflozin protects against nonalcoholic steatohepatitis in db\/db mice. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.934136"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/00365520902845268","article-title":"Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial","volume":"44","author":"Haukeland","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"104799","DOI":"10.1016\/j.phrs.2020.104799","article-title":"The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials","volume":"159","author":"Jalali","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/nm.3372","article-title":"Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin","volume":"19","author":"Fullerton","year":"2013","journal-title":"Nat. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"155516","DOI":"10.1016\/j.metabol.2023.155516","article-title":"Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis","volume":"141","author":"Park","year":"2023","journal-title":"Metabolism"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.7150\/ijbs.7.645","article-title":"Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription","volume":"7","author":"Yap","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"108802","DOI":"10.18632\/oncotarget.22163","article-title":"Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK\/LXR\u03b1 signaling pathway","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"120070","DOI":"10.1016\/j.lfs.2021.120070","article-title":"Blunting p38 MAPK\u03b1 and ERK1\/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-\u03baB inactivation in mice intoxicated with carbon tetrachloride","volume":"286","author":"Abdelhamid","year":"2021","journal-title":"Life Sci."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Arefin, A., and Gage, M.C. (2023). Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054785"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Rong, L., Zou, J., Ran, W., Qi, X., Chen, Y., Cui, H., and Guo, J. (2023). Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1087260"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Mascolo, A., Di Napoli, R., Balzano, N., Cappetta, D., Urbanek, K., De Angelis, A., Scisciola, L., Di Meo, I., Sullo, M.G., and Rafaniello, C. (2022). Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1010693"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s13340-015-0212-4","article-title":"Glucose area under the curve during oral glucose tolerance test as an index of glucose intolerance","volume":"7","author":"Sakaguchi","year":"2015","journal-title":"Diabetol. Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Lifante, J., de la Fuente-Fern\u00e1ndez, M., Rom\u00e1n-Carmena, M., Fernandez, N., Garc\u00eda, D.J., Granado, M., and Ximendes, E. (2022). In vivo grading of lipids in fatty liver by near-infrared autofluorescence and reflectance. J. Biophotonics, 16.","DOI":"10.1002\/jbio.202200208"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7873","DOI":"10.1038\/s41598-021-87020-5","article-title":"Regulation of plasma triglyceride partitioning by adipose-derived ANGPTL4 in mice","volume":"11","author":"Spitler","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_72","first-page":"461","article-title":"Wood smoke exposure induces a decrease in respiration parameters and in the activity of respiratory complexes I and IV in lung mitochondria from guinea pigs","volume":"30","author":"Ramos","year":"2013","journal-title":"Environ. Toxicol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"8531975","DOI":"10.1155\/2021\/8531975","article-title":"Role of the Transient Receptor Potential Vanilloid Type 1 (TRPV1) in the Regulation of Nitric Oxide Release in Wistar Rat Aorta","volume":"2021","author":"Arenas","year":"2021","journal-title":"Oxidative Med. Cell. Longev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/9010\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:30Z","timestamp":1760035590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/9010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":73,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26189010"],"URL":"https:\/\/doi.org\/10.3390\/ijms26189010","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]}}}